Company Filing History:
Years Active: 2024-2025
Title: Qing Song Liu: Innovator in Kinase Inhibitors
Introduction
Qing Song Liu is a notable inventor based in Anhui, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. With a total of 2 patents, his work focuses on innovative compounds that target specific kinase activities.
Latest Patents
One of his latest patents is titled "Pyrazole derivatives and use thereof." This invention provides a novel PDGFR kinase inhibitor, which includes a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The patent outlines the use and method of this compound for preventing or treating conditions associated with PDGFR kinase activity, particularly those related to PDGFRα and/or PDGFRβ kinase activity. Another significant patent is "Pan-RAF kinase inhibitor and use thereof." This invention also presents a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The patent details the use or method of this compound in the treatment or prevention of disorders related to the activity of RAF and/or RAS kinase.
Career Highlights
Qing Song Liu is currently associated with Therapeutics Science Inc., where he continues to advance his research in kinase inhibitors. His work has the potential to impact various therapeutic areas, particularly in oncology and other diseases linked to kinase activity.
Collaborations
He collaborates with notable colleagues, including Jing Liu and Xi Li, who contribute to his research endeavors. Their combined expertise enhances the innovative potential of their projects.
Conclusion
Qing Song Liu is a prominent figure in the field of medicinal chemistry, with a focus on kinase inhibitors. His patents reflect his commitment to developing novel therapeutic solutions. His work continues to pave the way for advancements in treating conditions associated with kinase activity.